# VSTM catalysts: Verastem, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/vstm/catalysts

> Verastem, Inc. (VSTM) has 18 upcoming catalysts. The next is the Erbitux® (cetuximab) interim data readout, early 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for VSTM?

Verastem, Inc. (VSTM) has 18 upcoming catalysts. The next is the Erbitux® (cetuximab) interim data readout, early 2027. Press release filed with the SEC (EX-99): "Report initial data from TARGET - D 101 mPDAC cohort evaluating VS - 7375 600 mg plus cetuximab in early 2027*." [Calendar and source filings](https://sec-api.dev/companies/vstm/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001104659-26-123386, https://www.sec.gov/Archives/edgar/data/1526119/000110465926123386/tm2628982d2_ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/companies/vstm/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Verastem, Inc. |
| Ticker | VSTM (Nasdaq) |
| SEC CIK | 1526119 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/vstm |

## Cash runway

Cash $172.8M as of 2026-09-30; quarterly burn $33.6M; about 15.4 months of runway at that rate (XBRL company facts, accession 0001104659-26-123305).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2022 | [Copiktra (duvelisib) FDA advisory committee meeting](https://sec-api.dev/pdufa/duvelisib) | VSTM | relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma | completed, negative | "In September 2022, the FDA's Oncologic Drug Advisory Committee ("ODAC") voted eight to four against COPIKTRA's use in patients with relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma after at least two prior therapies citing an unfavorable risk/benefit profile." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231x10k.htm)) |
| Jun 2024 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "GFH375 in China) was approved in China in June 2024, and the first patient was dosed in a Phase 1/2 study in July 2024." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465925101817/tm2529362d1_8k.htm)) |
| December 30, 2024 | [AVMAPKI (avutometinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/avutometinib) | VSTM |  | completed | "On December 30, 2024, the FDA accepted for review our NDA under the accelerated approval pathway and granted priority review for avutometinib and defactinib for treatment of adult patients with recurrent KRAS mt LGSOC who received at least one prior systemic therapy and designated June 30, 2025 as the Prescription Drug User Fee Act ("PDUFA") action date." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000155837025003372/vstm-20241231x10k.htm)) |
| Jan 2025 | [VS-7375 FDA approval](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed, approved | "We exercised the GenFleet Option (defined herein) in January 2025, announced that our IND application for VS-7375 had been approved by the FDA in April 2025, and initiated a Phase 1/2a clinical trial in June 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm)) |
| Jan 2025 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "We exercised the GenFleet Option (defined herein) in January 2025, announced that our IND application for VS-7375 had been approved by the FDA in April 2025, and initiated a Phase 1/2a clinical trial in June 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm)) |
| Apr 2025 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "The Company announced in April 2025 that the U.S. Investigational New Drug ("IND") application for VS-7375 was cleared and initiated a Phase 1/2a clinical trial in June 2025." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465925100537/tm2529024d1_8k.htm)) |
| mid-2025 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | scheduled | "Verastem announced in April 2025 that the U.S. Investigational New Drug (IND) application for VS-7375 was cleared and plans to initiate a Phase 1/2a clinical trial in mid-2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925055286/tm2516844d1_ex99-1.htm)) |
| May 8, 2025 | [FAKZYNJA (defactinib) PDUFA date](https://sec-api.dev/pdufa/defactinib) | VSTM |  | scheduled | "On May 8, 2025, the FDA approved AVMAPKI FAKZYNJA CO-PACK in advance of its Prescription Drug User Fee Act or PDUFA action date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465925106279/vstm-20250930x10q.htm)) |
| May 8, 2025 | [Avmapki Fakzynja Co-Pack (Copackaged) (avutometinib potassium; defactinib hydrochloride) FDA approval](https://sec-api.dev/pdufa/avutometinib-defactinib) | VSTM |  | completed, approved | "NDA219616 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20250508, review_priority PRIORITY; sponsor_name VERASTEM INC; product AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) (AVUTOMETINIB POTASSIUM; DEFACTINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219616%22)) |
| May 8, 2025 | [AVMAPKI (avutometinib) FDA approval](https://sec-api.dev/pdufa/avutometinib) | VSTM | RAS/MAPK pathway-driven cancers, today | completed, approved | "On May 8, 2025, Verastem, Inc. issued a press release announcing that the United States Food and Drug Administration ("FDA") has approved AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets) for the treatment of adult patients with recurrent Kirsten rat sarcoma viral oncogene homolog mutated ("KRAS mt") low-grade serous ovarian cancer ("LGSOC") who received prior systemic therapy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465925046175/tm2514525d1_8k.htm)) |
| Jun 2025 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM | advanced KRAS G12D mutant solid tumors | completed | "Verastem initiated VS-7375-101, a Phase 1/2a clinical trial, in June of 2025 in the U.S., with the potential to expand globally, that is evaluating the safety and efficacy of VS-7375 in patients with advanced KRAS G12D mutant solid tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm)) |
| June 30, 2025 | [AVMAPKI (avutometinib) PDUFA date](https://sec-api.dev/pdufa/avutometinib) | VSTM |  | completed, approved | "Avutometinib and Defactinib in Recurrent Low - Grade Serous Ovarian Cancer (LGSOC) PDUFA Action Date: June 30, 2025 Potential Launch in KRAS mutant Recurrent LGSOC in mid - 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925026130/tm259913d1_ex99-1.htm)) |
| June 30, 2025 | [FAKZYNJA (defactinib) PDUFA date](https://sec-api.dev/pdufa/defactinib) | VSTM | with KRAS-mutated recurrent LGSOC | scheduled | "AVMAPKI FAKZYNJA CO-PACK received accelerated approval by the U.S. Food and Drug Administration (FDA) on May 8, 2025 for the treatment of adults with KRAS-mutated recurrent LGSOC who have received prior systemic therapy, approximately two months in advance of the Prescription Drug User Fee Act ("PDUFA") action date of June 30, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926023444/vstm-20251231x10k.htm)) |
| October 22, 2025 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "GenFleet also shared that the first patient has been dosed in a Phase 1b/2 study of GFH375 combined with cetuximab or chemotherapy for advanced solid tumors on October 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm)) |
| November 4, 2025 | [Verastem, Inc. earnings report](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "BOSTON--(BUSINESS WIRE)—Nov. 4, 2025--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for the third quarter ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925105923/tm2530140d1_ex99-1.htm)) |
| December 2025 | [Avutometinib (vs-6766) + defactinib (vs-6063) primary completion](https://sec-api.dev/pdufa/avutometinib-vs-6766-defactinib-vs-6063) | VSTM | Low Grade Serous Ovarian Cancer; Ovarian Cancer | delayed | "NCT06682572 (A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-12 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06682572)) |
| June 16, 2026 | [VS-7375 trial start](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | completed | "On June 16, 2026, the Company also announced that the first patient has been dosed in the TARGET-D 201 Phase 2 registration-directed trial evaluating VS-7375, an investigational oral" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926074915/tm2618108d1_8k.htm)) |
| June 23, 2026 | [Erbitux® (cetuximab) trial start](https://sec-api.dev/pdufa/cetuximab) | VSTM |  | completed | "Announce first patient dosed in the TARGET-D 202 and TARGET-D 203 clinical trials in mid-2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1526119/000110465926076809/tm2618546d1_8k.htm)) |
| August 6, 2026 | [Verastem, Inc. trial start](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "July 28, July 22, and June 16, the Company announced the first patient was dosed in the TARGET-D" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_ex99-1.htm)) |
| August 6, 2026 | [Verastem, Inc. earnings report](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "Aug. 6, 2026-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092058/tm2622452d2_ex99-1.htm)) |
| late 2026 | [Erbitux® (cetuximab) interim data readout](https://sec-api.dev/pdufa/cetuximab) | VSTM |  | scheduled | "Expect to report mature data from TARGET - D 101 mCRC 900mg combination cohort and initial data from the mPDAC cetuximab cohort at 600 mg by end of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-3.htm)) |
| late 2026 | [VS-7375 interim data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | scheduled | "Plan to report mature data from the TARGET-D 101 mCRC 900 mg combination with anti-EGFR cohort and initial data from the 600 mg VS-7375 plus cetuximab combination cohort in mPDAC by year-end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm)) |
| Oct 2026 | [AVMAPKI (avutometinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/avutometinib) | VSTM |  | completed | "Ø In October 2026, we communicated that the FDA had accepted the New Drug Application ("NDA") for the AVMAPKI FAKZYNJA CO-PACK Blister Pack, granting it priority review with a FDA decision by February 7, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-20260930x10q.htm)) |
| October 7, 2026 | [Verastem, Inc. NDA/BLA acceptance](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | completed | "On October 7, 2026, the FDA accepted for review our Blister Pack New Drug Application (the "NDA") for the first quarter of 2027 and notified us that the NDA has been granted priority review." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115875/tm2627537-1_424b5.htm)) |
| early 2027 | [Erbitux® (cetuximab) interim data readout](https://sec-api.dev/pdufa/cetuximab) | VSTM |  | scheduled | "Report initial data from TARGET - D 101 mPDAC cohort evaluating VS - 7375 600 mg plus cetuximab in early 2027*." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123386/tm2628982d2_ex99-1.htm)) |
| February 7, 2027 | [Verastem, Inc. PDUFA date](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | scheduled | "FDA decision on NDA for AVMAPKI FAKZYNJA CO - PACK Blister Pack by February 7, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123386/tm2628982d2_ex99-1.htm)) |
| mid-2027 | [FAKZYNJA (defactinib) topline data readout](https://sec-api.dev/pdufa/defactinib) | VSTM |  | scheduled | "+ Defactinib vs ICT Recurrent LGSOC Expect to report topline readout of primary endpoint by mid-2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_ex99-1.htm)) |
| Q2 2027 | [Verastem, Inc. interim data readout](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | scheduled | "Expect to report initial data from Phase 2 TARET - D 201 2L PDAC trial in Q2 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-3.htm)) |
| Q2 2027 | [Gemzar (gemcitabine) interim data readout](https://sec-api.dev/pdufa/gemcitabine) | VSTM |  | scheduled | "Ø We expect to report initial data from the 1L mPDAC combination with gemcitabine/nab-paclitaxel at the start of the second quarter of 2027, with the data intended for presentation at a medical meeting." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-20260930x10q.htm)) |
| mid-2027 | [Verastem, Inc. topline data readout](https://sec-api.dev/companies/vstm/catalysts) | VSTM |  | scheduled | "3 confirmatory trial in recurrent LGSOC completes additional patient enrollment; topline data anticipated in mid-2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/tm2533463d1_ex99-1.htm)) |
| Q2 2027 | [VS-7375 interim data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM |  | scheduled | "Plan to report initial data from Phase 2 TARGET-D 201 2L PDAC in Q2 2027;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1526119/000110465926115687/tm2627537d4_ex99-2.htm)) |
| mid-2027 | [AVMAPKI (avutometinib) topline data readout](https://sec-api.dev/pdufa/avutometinib) | VSTM | recurrent LGSOC | scheduled | "Ø We expect to report a topline readout of the primary endpoint in the RAMP 301 trial of avutometinib plus defactinib in patients with recurrent LGSOC in the middle of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1526119/000110465926123305/vstm-20260930x10q.htm)) |
| June 2027 | [VS-7375 primary completion](https://sec-api.dev/pdufa/vs-7375) | VSTM | Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS | scheduled | "NCT07644559 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07644559)) |
| Jun to Sep 2027 | [VS-7375 topline data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM | Pancreatic Ductal Adenocarcinoma (PDAC); G12D Mutated KRAS | scheduled | "NCT07644559 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07644559)) |
| June 2027 | [VS-7375 primary completion](https://sec-api.dev/pdufa/vs-7375) | VSTM | Non-Small Cell Lung Cancer | scheduled | "NCT07659782 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659782)) |
| Jun to Sep 2027 | [VS-7375 topline data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM | Non-Small Cell Lung Cancer | scheduled | "NCT07659782 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659782)) |
| June 2027 | [VS-7375 primary completion](https://sec-api.dev/pdufa/vs-7375) | VSTM | Colorectal Cancer | scheduled | "NCT07659795 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659795)) |
| Jun to Sep 2027 | [VS-7375 topline data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM | Colorectal Cancer | scheduled | "NCT07659795 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659795)) |
| August 2027 | [Avutometinib + defactininb combination primary completion](https://sec-api.dev/pdufa/avutometinib-defactininb-combination) | VSTM | Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer | scheduled | "NCT07747506 (Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-01 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747506)) |
| Aug to Nov 2027 | [Avutometinib + defactininb combination topline data readout](https://sec-api.dev/pdufa/avutometinib-defactininb-combination) | VSTM | Low Grade Ovarian Serous Adenocarcinoma; Ovarian Cancer | scheduled | "NCT07747506 (Continued Access to Avutometinib in Combination With Defactinib in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-08-01 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07747506)) |
| Oct 2028 to Jan 2029 | [AVMAPKI (avutometinib) topline data readout](https://sec-api.dev/pdufa/avutometinib) | VSTM | Low Grade Serous Ovarian Cancer | scheduled | "NCT06072781 (A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-15 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06072781)) |
| October 2028 | [AVMAPKI (avutometinib) primary completion](https://sec-api.dev/pdufa/avutometinib) | VSTM | Low Grade Serous Ovarian Cancer | scheduled | "NCT06072781 (A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-15 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06072781)) |

## Drugs

- [AVMAPKI (avutometinib)](https://sec-api.dev/pdufa/avutometinib): recurrent lgsoc, ras/mapk pathway-driven cancers, today, Low Grade Serous Ovarian Cancer
- [Avmapki Fakzynja Co-Pack (Copackaged) (avutometinib potassium; defactinib hydrochloride)](https://sec-api.dev/pdufa/avutometinib-defactinib): 
- [Avutometinib + defactininb combination](https://sec-api.dev/pdufa/avutometinib-defactininb-combination): Low Grade Ovarian Serous Adenocarcinoma
- [Avutometinib (vs-6766) + defactinib (vs-6063)](https://sec-api.dev/pdufa/avutometinib-vs-6766-defactinib-vs-6063): Low Grade Serous Ovarian Cancer
- [FAKZYNJA (defactinib)](https://sec-api.dev/pdufa/defactinib): with kras-mutated recurrent lgsoc
- [Copiktra (duvelisib)](https://sec-api.dev/pdufa/duvelisib): relapsed or refractory chronic lymphocytic leukemia/ small lymphocytic lymphoma
- [VS-7375](https://sec-api.dev/pdufa/vs-7375): advanced kras g12d mutant solid tumors, advanced, Pancreatic Ductal Adenocarcinoma (PDAC), Non-Small Cell Lung Cancer, Colorectal Cancer

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/vstm/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VSTM catalysts: Verastem, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/vstm/catalysts

```bibtex
@misc{secapidev_companies_vstm_catalysts_20261116,
  title        = {VSTM catalysts: Verastem, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/vstm/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_vstm_catalysts_20261116","title":"VSTM catalysts: Verastem, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/vstm/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
